UCB Aims High In Hidradenitis Suppurativa After Bimzelx Success
Set To Challenge Humira In Skin Disease
Topline results from two Phase III studies show the Belgian group's dual IL-17A and IL-17F inhibitor met its primary and secondary endpoints ahead of a filing for hidradenitis suppurativa next year. How well it compares with Humira and Cosentyx in this indication remains to be seen, however.
You may also be interested in...
An EU decision in hidradenitis suppurativa is important, but the long-delayed US decision in psoriasis – and the specifics of the label – is even more so.
The Swiss major should have a considerable first-to-market advantage over other IL-17 biologics from the likes of UCB and Acelyrin that are also targeting the hidradenitis suppurativa space.
The US Food and Drug Administration has published a report after an inspection of UCB’s Belgian facility where Bimzelx is manufactured and the findings suggest that a long-awaited approval for the psoriasis drug should not be taken for granted.